Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618
What this trial is testing

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Not applicableLooking for participantsNCT06171360
What this trial is testing

The Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 100
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Testing effectiveness (Phase 2)Ended earlyNCT00759642
What this trial is testing

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 33
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Not applicableActive Not RecruitingNCT04030507
What this trial is testing

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer+3 more
Brigham and Women's Hospital 214
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944434
What this trial is testing

FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 116
Very early researchNot Yet RecruitingNCT07671092
What this trial is testing

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Who this might be right for
Metastatic Urothelial CarcinomaBreast CancerTNBC - Triple-Negative Breast Cancer+2 more
RayzeBio, Inc. 40
Early research (Phase 1)Study completedNCT03524170
What this trial is testing

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
M.D. Anderson Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT02990845
What this trial is testing

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Premenopausal Breast Cancer
National Taiwan University Hospital 16
Testing effectiveness (Phase 2)Looking for participantsNCT06518837
What this trial is testing

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Rutgers, The State University of New Jersey 40
Not applicableStudy completedNCT05377684
What this trial is testing

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment

Who this might be right for
Early-stage Breast Cancer
Ipsen 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT04553133
What this trial is testing

PF-07104091 as a Single Agent and in Combination Therapy

Who this might be right for
Small Cell Lung CancerOvarian CancerBreast Cancer
Pfizer 157
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Next Page